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Abstract: Phytochemical investigation on the methanol extract of Woodwardia unigemmata resulted
in the isolation of seven flavonoids, including one new flavonol acylglycoside (1). The structures of
these compounds were elucidated on the basis of extensive spectroscopic analysis and comparison
of literature data. The multidrug resistance (MDR) reversing activity was evaluated for the isolated
compounds using doxorubicin-resistant K562/A02 cells model. Compound 6 showed comparable
MDR reversing effect to verapamil. Furthermore, the interaction between compounds and bovine
serum albumin (BSA) was investigated by spectroscopic methods, including steady-state fluorescence,
synchronous fluorescence, circular dichroism (CD) spectroscopies, and molecular docking approach.
The experimental results indicated that the seven flavonoids bind to BSA by static quenching
mechanisms. The negative ∆H and ∆S values indicated that van der Waals interactions and hydrogen
bonds contributed in the binding of compounds 2–6 to BSA. In the case of compounds 1 and 7
systems, the hydrophobic interactions play a major role. The binding of compounds to BSA causes
slight changes in the secondary structure of BSA. There are two binding sites of compound 6 on BSA
and site I is the main site according to the molecular docking studies and the site marker competitive
binding assay.
Keywords: Woodwardia unigemmata; multidrug resistance; doxorubicin-resistant K562/A02 cells;
bovine serum albumin; molecular docking
1. Introduction
Multidrug resistance (MDR) renders the insensitivity of cancer cells to a diverse panel of anticancer
agents, and it is the largest obstacle to cancer chemotherapy. A wide variety of natural products
belonging to different classes have been found to have MDR-modulating activity [1,2]. Nevertheless,
none of the MDR-reversal agents currently is available for clinical use, as they suffered from
unpredictable pharmacokinetic behavior and toxicity [3]. Therefore, the exploration and development
of potent and safe MDR reversal agents is still urgently needed.
Serum albumin (SA), a type of globular protein, is the most plentiful blood protein in mammals.
The distribution of drugs is usually directed by SA, as most drugs circulate in plasma and reach the
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targeted tissues via binding to SA [4]. Therefore, the binding of drugs to SA turned into an essential
determinant of pharmacokinetics restricting the unbound concentration and affecting distribution and
elimination. Bovine serum albumin (BSA) is an important mode protein, which contains 583 amino
acids with twenty tyrosyl (Tyr) residues and two tryptophan (Trp134, Trp213) residues [5]. Its structure
looks like heart-shaped and that it is composed of three specific homologous domains I, II and III.
Each domain has A and B subdomains. The principal regions of drugs’ binding sites of albumin are
often located in hydrophobic cavities in sub-domains IIA and IIIA. Site I (located in subdomain IIA)
is a selective binding site for heterocyclic anions, while site II (located in subdomain IIIA) is selected
by aromatic carboxylates. Recently, BSA is frequently used as a model protein for the evaluation of
interaction between drugs and protein because of its structural similarity (75.6%) with human serum
albumin (HSA), low cost, ready availability and some usual ligand binding properties [6].
Ferns as a very ancient family of plants can predate the beginning of the Mesozoic era, 252 million
years ago. Various types of natural compounds have been discovered from different fern species
during the last decade [7,8]. In the current work, an extract of Woodwardia unigemmata (Makino) Nakai
was chemically investigated and the obtained compounds were tested with MDR reversing effects.
In our ongoing research for plant-derived MDR-reversal agents [9,10], we report the isolation
and structure determination of seven flavonoids, including one new compound, from the whole
plants of W. unigemmata. Compounds 1–7 were evaluated for their cytotoxicity towards K562 cells
and multidrug resistance reversing activity on human myelogenous leukemia cells. Furthermore,
compounds binding to BSA are studied using multi-spectroscopic and molecular modeling methods.
Interaction information from quenching mechanisms, binding parameters, thermodynamic parameters
and binding modes is reported in the present work. Molecular interactions were characterized using
molecular docking studies.
2. Results and Discussion
2.1. Structure Elucidation of Compounds 1–7
The methanol extract of the rhizomes of W. japonica was fractionated and purified by repeated
column chromatography as described in the experimental section, leading to the isolation of a new
compound 1 along with six known compounds 2–7 (Figure 1).
Compound 1 was obtained as an amorphous powder with the molecular formula C33H36O17, as
determined by HR-ESI-MS (m/z 705.2027 [M + H]+; calc. 705.2025). The 1H- and 13C-NMR (Table 1)
spectra indicated that 1 was a flavonol with glycosidic and acyl moieties. The chemical shift and
coupling constant data of the aromatic protons together with their corresponding 13C-NMR chemical
shifts obtained from Heteronuclear Single Quantum Correlation (HSQC) and Heteronuclear Multiple
Bond Correlation (HMBC) experiments confirmed the identity of kaempferol as the aglycone [11].
The 1H-NMR also indicated the presence of two sugar moieties with two anomeric protons at δH
5.64(1H, brs, H-1′ ′) and 5.58 (1H, brs, H-1′ ′ ′), which correspond to the carbon signals at δC 100.5
and 98.1 in the HSQC spectrum. Thus, the glycosyl moiety of 1 consisted of two sugar units. Two
rhamnosyl moieties were presumed by analysis of the 13C-NMR data for monosaccharide. After sugar
composition analysis, the presence of two L-rhamnose was confirmed [12,13]. The α-configuration
of the rhamnose units were observed from the slight broadening of the appropriate H-1′ ′ and H-1′ ′ ′
signals [14]. The presence of the HMBC correlations between the rhamnosyl anomericproton H-1′ ′ at
δH 5.64 and the resonance of C-3 at δC 134.1, and between the rhamnosyl anomericproton H-1′ ′ ′ at δH
5.58 and the resonance of C-7 at δC 130.6 suggested glycosidation at C-3 and C-7.
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1′′ 5.64 d (1.2) 100.5 C-3, C-2′′ 
2′′ 4.36 m 67.7 C-1′′, C-3′′ 
3′′ 5.18 dd (10.2 3.0) 71.3 C-4′′, 3′′-COCH3 
4′′ 5.05 t (10.2) 70.3 C-5′′, 4′′-COCH3 
5′′ 3.78 m 68.3 C-4′′, C-6′′ 
6′′ 0.84 d(6.0) 16.1 C-4′′, C-5′′ 
1′′′ 5.58 m 98.5 C-7, C-2′′ 
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Figure 1. Structures of compounds 1–7.
Table 1. 1H-NMR (600 MHz) and 13C-NMR (150 MHz) data of compound 1 in CD3OD.
Position δH (J in Hz) δC HMBC (H→ C)
2 158.5
3 134.0
4 178.1
5 161.6
6 6.52 d (1.8) 99.2 C-5, C-7, C-8
7 162.2
8 6.79 d (1.8) 94.2 C-7, C-10, C-6
9 156.7
10 106.2
1′ 120.8
2′ 7.82 d (8.4) 130.6 C-1′, C-3′/5′, C-4′
3′ 7.00 d (8.4) 115.3 C-1′, C-2′/6′, C-4′
4′ 160.6
5′ 7.00 d (8.4) 115.3 C-1′, C-2′/6′, C-4′
6′ 7.82 d (8.4) 130.6 C-1′, C-3′/5′, C-4′
1′ ′ 5.64 d (1.2) 100.5 C-3, C-2′ ′
2′ ′ 4.36 m 67.7 C-1′ ′, C-3′ ′
3′ ′ 5.18 dd (10.2 3.0) 71.3 C-4′ ′, 3′ ′-COCH3
4′ ′ 5.05 t (10.2) 70.3 C-5′ ′, 4′ ′-COCH3
5′ ′ 3.78 m 68.3 C-4′ ′, C-6′ ′
6′ ′ 0.84 d(6.0) 16.1 C-4′ ′, C-5′ ′
1′ ′ ′ 5.58 m 98.5 C-7, C-2′ ′
2′ ′ ′ 4.24 m 73.3 C-1′ ′ ′, C-3′ ′ ′,
3′ ′ ′ 4.06 dd (9.6 3.0) 70.4 C-2′ ′ ′, C-4′ ′ ′
4′ ′ ′ 4.78 t (9.6) 73.3 C-3′ ′ ′, 4′ ′ ′-COCH3
5′ ′ ′ 3.33 m 69.9 C-4′ ′ ′, C-6′ ′ ′
6′ ′ ′ 1.17 d (6.0) 16.7 C-5′ ′ ′
3′ ′-COCH3 170.7
3′ ′-COCH3 2.10 s 19.4 3′ ′-COCH3
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Table 1. Cont.
Position δH (J in Hz) δC HMBC (H→ C)
4′ ′-COCH3 170.3
4′ ′-COCH3 2.00 s 19.2 4′ ′-COCH3
4′ ′ ′-COCH3 170.9
4′ ′ ′-COCH3 1.96 s 19.5 4′ ′ ′-COCH3
The remaining sub-structure of 1 was deduced by analysis of the 1H-, 13C- and 2D-NMR
spectroscopic data to possess three acetoxy groups [δH 2.13 (3H, s), 2.05 (3H, s) and 1.99 (3H, s)].
The acetyl groups were determined to be linked at the C-3′ ′, C-4′ ′ and C-4′ ′ ′ due to the presence of the
cross-peaks between in the HMBC spectrum (Figure 2). Accordingly, the structure of 1 was elucidated
as kaempferol3-O-α-L-(3,4-O-di-acetyl) rhamopyranoside-7-O-α-L-(4-O-acetyl) rhamnopyranoside.
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Figure 2. Key HMBC correlations of compound 1.
The six known compounds crassirhizomoside B (2), crassirhizomoside C (3),
kaempferol 3-O-α-L-(3-O-acetyl) rhamopyranoside-7-O-α-L-rhamnopyranoside (4), kaempferol
3-O-α-L-(2-O-acetyl) rhamopyranoside-7-O-α-L-rhamnopyranoside (5), sutchuenoside A (6), and
kaempferol 3-O-α-L-rhamopyranoside-7-O-α-L-rhamnopyranoside (7) were identified on the basis of
their spectroscopic profiles and comparison to the published data [15–17].
2.2. Pharmacological Studies
To determi e the reversal effect of compounds 1–7 on resistant tumor cells, the cytotoxicity
of the compounds toward K562, and their MDR variants K562/A02 cells was first measured
by th MTT method. All compounds showed no cytotoxicity to both cell lines. The ability
of compounds 1–7 to reverse MDR to doxorubicin (DOX) in cancer cells was investigated at a
non-cytotoxic concentration (10 µM). Those compounds overcame the multidrug resistance (MDR)
for doxorubicin-resistant K562/A02 cells, and the tested compounds showed the remarkable reversal
effect (Table 2). Verapamil was a positive control. Those compounds are potential natural products
that deserve more investigations to develop novel drugs against multifactorial drug-resistant cancers.
Table 2. Effects of compound 1–7 (10 µM) on doxorubicin (DOX) cytotoxicity in K562 cells
and K562/A02cells. Half maximal inhibitory concentration(IC 50) values (µM) for DOX were
calculated and the reversal folds (RF) were evaluated. Data were expressed as means ± SD of five
independent experiments.
Compounds IC50 (K562) IC50 (K562/A02) RF (K562/A02)
DOX 0.66 ± 0.12 19.2 ± 0.31
DOX + Verapamil 0.58 ± 0.23 2.12 ± 0.19 9.06
DOX + 1 0.67 ± 0.11 5.18 ± 0.17 3.71
DOX + 2 0.62 ± 0.08 4.14 ± 0.33 4.64
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Table 2. Cont.
Compounds IC50 (K562) IC50 (K562/A02) RF (K562/A02)
DOX + 3 0.69 ± 0.10 3.74 ± 0.12 5.13
DOX + 4 0.70 ± 0.24 3.04 ± 0.33 4.75
DOX + 5 0.65 ± 0.16 5.14 ± 0.12 3.74
DOX + 6 0.68 ± 0.12 2.31 ± 0.10 8.31
DOX + 7 0.60 ± 0.22 3.93 ± 0.26 5.94
2.3. Fluorescence Quenching of BSA Induced by Compounds
Fluorescence measurements were performed to investigate whether compounds 1–7 interact with
BSA. The intrinsic fluorescence of BSA is caused by Trp, Tyr, and Phe residues. Trp residues dominate
the fluorescence spectrum of BSA due to its high quantum yield and the ability to quench the emission
of Tyr and Phe residues through energy transfer [6]. BSA intramolecular forces and conformation can
be affected and changed by small molecule binding.
To correct the inner filter effects of compounds and BSA, fluorescence intensity was calculated as:
Fcor = Fobs10
1
2
(Aex +Aem), (1)
where Fcor and Fobs are the corrected and observed fluorescence intensities, respectively, and Aex and
Aem are the absorption of the systems at the excitation and emission wavelength, respectively. All
fluorescence data mentioned in this work is intensity corrected.
The fluorescence quenching spectra of BSA at various concentrations of compounds are shown in
Figure 3. The Figure 3A–G indicates the compounds’ concentration dependent fluorescence quenching
of BSA in the presence of 0–30 µM compounds. Despite the considerable fluorescence quenching in
BSA, the emission maxima remained unchanged throughout the addition.
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Figure 3. The fluorescence quenching spectra of BSA (5 µM) with variable concentrations of compounds
1 (A), 2 (B), 3 (C), 4 (D), 5 (E), 6 (F), 7 (G) at the excitation wavelength (280 nm) in 0.05 mol L−1 Tris-HCl,
pH 7.4. The concentrations of compounds varied from 0 to 30 µM.
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Fluorescence quenching is characterized by two types of mechanisms, usually classified as
dynamic and static. Dynamic quenching refers to a process that involves the fluorophore and the
quencher coming into contact during transient existence of the excited state, whereas static quenching
refers to the formation of fluorophore-quencher complex [18]. Fluorescence quenching is described by
the Stern–Volmer equation:
F0
F
= 1+KSV[Q] = 1+Kqt0[Q], (2)
where F0 and F are the fluorescence intensities before and after the addition of the quencher,
respectively, kq is the bimolecular quenching constant, τ0 is the lifetime of the fluorophore in the
absence of the quencher (τ0 = 10−8 s), [Q] is the concentration of the quencher, and Ksv is the
Stern–Volmer quenching constant. Hence, the Stern–Volmer equation was applied to determine
Ksv and kq by linear regression of F0/Fsv [Q] [19]. Ksv is shown in Table 3. Figure 4 shows the modified
Stern–Volmer plots of the fluorescence quenching of BSA by compounds at different temperatures
(289 K, 297 K and 307 K).
Table 3. Binding and thermodynamic parameters for the interaction between compounds 1–7 and BSA
at different temperatures, pH = 7.4.
NO T (K) Ksv (×10
4
L·mol−1) R
2 Kq (×1012
L·mol−1·s−1) Log Kb
Kb (×105
L·mol−1) n R
2 ∆G
(KJ·mol−1)
∆H
(KJ·mol−1)
∆S
(J·mol−1·K−1)
1
289 1.6 0.994 1.6 4.472 0.3 1.06 0.994
297 1.49 0.991 1.49 4.616 0.41 1.1 0.992 −26.25 67.1 316.68
307 1.3 0.995 1.3 5.082 1.21 1.22 0.996
2
289 2.76 0.996 2.76 5.332 2.15 1.1 0.986
297 2.24 0.995 2.24 4.757 0.57 1.09 0.997 −27.05 −84.47 −191.14
307 1.79 0.993 1.79 4.589 0.39 1.06 0.991
3
289 2.77 0.993 2.77 4.701 0.5 1.06 0.995
297 2.26 0.99 2.26 4.675 0.47 1.07 0.997 −26.58 −29.55 −11.55
307 1.99 0.992 1.99 4.43 0.27 1.03 0.991
4
289 2.5 0.993 2.5 5.265 1.84 1.2 0.985
297 2.14 0.998 2.14 5.027 1.06 1.16 0.996 −28.58 −89.64 −208.18
307 1.87 0.992 1.87 4.453 0.28 1.04 0.998
5
289 2.91 0.995 2.91 5.277 1.89 1.19 0.998
297 2.4 0.996 2.4 4.984 0.96 1.14 0/995 −28.34 −54.79 −88.71
307 2.14 0.996 2.14 4.79 0.62 1.11 0.993
6
289 2.29 0.996 2.29 4.894 0.78 1.08 0.997
297 2.11 0.993 2.11 4.662 0.46 1.08 0.996 −26.69 −38 −38.1
307 1.75 0.995 1.75 4.558 0.36 1.07 0.996
7
289 2.74 0.998 2.74 3.819 0.07 0.9 0.997
297 1.53 0.996 1.53 4.327 0.21 1.03 0.998 −24.6 90.73 387.43
307 1.4 0.998 1.4 4.624 0.42 1.11 0.998
From the results of the Table 3 and Figure 4A–G, the quenching constant Ksv of these systems
are decreased with increase in temperature indicating a static quenching mechanism of the protein
fluorescence. Furthermore, values of kq were calculated for the interaction of these compounds with
BSA. kq values were found to be of the order of 1012, which are 100 times greater than maximum
scatter collision quenching constant value 2.0 × 1010 L mol−1 s−1. It indicates that compounds interact
with BSA in the static quenching manner [20]. Equation (3) is used to calculate the binding constant
(Kb) and number of binding sites (n) [21]:
log
(
F0 − F
F
)
= logKb + nlog[Q], (3)
where F and F0 are fluorescence intensities with and without quencher, respectively. Kb is binding
constant, n is the number of binding sites per BSA molecule and [Q] is the concentration of compounds.
Figure 5 shows the binding equilibrium plots for the fluorescence quenching of BSA by compounds
1–7 at 289, 297 K and 307 K. Values of Kb and n gained from Equation (3) are given in Table 3. The
number of binding sites in all systems approximates to 1 indicating that only one binding site in protein
is reactive to the compounds 1–7. The binding constants Kb of 2–6 are decreased with increasing
Molecules 2017, 22, 1317 7 of 19
temperature, which was in accordance with the change of Ksv. The Kb of compounds 1 and 7 are
increased with the increasing temperature, which is denoted differently with respect to compounds
2–6.
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2.4. Types of Interaction Forces between BSA and Compounds
The binding forces contributing to protein interactions with small molecular substrates often
include van der Waals interactions, hydrophobic forces, electrostatic interactions, and hydrogen
bonding. The signs and magnitudes of thermodynamic parameters, such as standard enthalpy change
(∆H), standard entropy change (∆S) and free energy (∆G) of binding reaction provide evidence for
binding mode between the small molecules and macromolecule. The thermodynamic parameters are
evaluated using the the Van’t Hoff e equations [22]:
LnKb = −∆H/RT+ ∆S/R, (4)
∆G = −RTlnKb, (5)
where K is the binding constant at the corresponding temperature, R is the gas constant, and T is
absolute temperature. Due to the ∆H and ∆S signs of the system, the binding mechanism between a
small molecule and protein can be determined. Accordingly, hydrophobic forces are dominant when
∆H > 0 and ∆S > 0, van der Waals interactions and hydrogen bonds contributed to binding when
∆H < 0 and ∆S < 0, and ∆H < 0 and ∆S > 0 are characteristics for electrostatic interactions [22,23].
The values of ∆H, ∆S and ∆G are listed in Table 3. The negative values of ∆G mean that the binding
process is spontaneous. The negative ∆H and ∆S values indicate that hydrogen bonds and van der
Waals forces played a major role in the interaction of the compounds 2–6 system. Both positive ∆S and
∆H in the case of compounds 1 and 7 suggest the presence of hydrophobic interactions.
2.5. Synchronous Fluorescence Spectroscopic Studies
Synchronous fluorescence spectroscopy is a very useful method to study the microenvironment
of amino acid residues by measuring the emission wavelength shift. The synchronous fluorescence
of protein at ∆λ = 15 nm and ∆λ = 60 nm are characteristic of Tyr and Trp residues, respectively. The
∆λ value represents the difference between excitation and emission wavelengths and is an important
parameter [24]. The synchronous fluorescence spectra of BSA in the presence of different concentration
of the compounds are shown in Figures 6 and 7. It can be seen that the intensities of synchronous
fluorescence gradually decreased upon addition of compounds, which is consistent with the steady
state fluorescence results. At the same time, the maximum emission wavelength almost does not
change when the ∆λ was set at 15 nm. A slight red shift take place at the ∆λ = 60 nm. However, no
shift was observed in fluorescence quenching experiments, suggesting a similar microenvironment
surrounding Trp residues upon ligands binding.
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2.6. Circular Dichroism Studies
In order to determine the effect of compounds binding on the secondary structure of BSA, a
circular dichroism (CD) spectroscopic analysis was performed. As can be observed in Figure 8, the CD
spectra of BSA exhibit two negative bands at 208 nm and 222 nm characteristic of α-helical structures
in the protein to gain an understanding on the results of the CD spectra of BSA in the presence of
compounds the α-helical content of BSA is evaluated from the following equations:
MER =
CD(mdeg)
10·n·l·Cp , (6)
α− helix(%) = −MER208 − 4000
33000− 4000 × 100, (7)
where MRE208 is mean residue ellipticity observed at 208 nm., Cp is the molar concentration of the
protein, n is the number of amino acid residues, and l is the path length of the cell. 4000 and 33,000 are
the MRE values of a β-form with random coil conformation and a pure α-helix at 208 nm, respectively.
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Figure 8. CD spectra of BSA (5 µM) in the presence of compounds 1 (A), 2 (B), 3 (C), 4 (D), 5 (E), 6 (F)
and 7 (G) in 0.05 ol L 1 Tris-HCl, pH 7.4. The concentrations of the compounds were 30 µM.
A molar ratio of 1:6 for BSA: compounds was used for the CD measurements. From the above
equations, the α-helix contents of BSA for the compound-BSA complexes are 60.12% for 1, 59.01%
for 2, 60. 08% for 3, 59.28% for 4, 59.59% for 5, 64.17% for 6, and 60.49% for 7, which are slightly
changed compared with the native BSA value (58.61%). It can be seen from the data that the binding
of compounds with BSA causes slight conformational change. These results are in agreement with
those obtained from synchronous fluorescence spectra.
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2.7. Energy Transfer from BSA to Compounds
Förster’s non-radiative energy transfer theory is widely used to estimate the spatial distances
between a biomolecule and a small molecule. The energy transfer efficiency (E) from the donor (BSA)
to the acceptor (the compounds) can be determined by the following equation [25,26]:
E = 1− F
F0
= R60/
(
r6 + R60
)
, (8)
where E is the energy transfer efficiency, F and F0 are the fluorescence intensities of BSA in the presence
and absence of compounds, r is the distance between acceptor and donor and R0 is the critical distance
when the transfer efficiency is 50%. The R0 can be calculated by Equation (10):
R60 = 8.8× 10−25k2N−4ΦJ, (9)
where k2 is the spatial orientation factor of the dipole with k2 = 2/3, N is the refractive index of the
medium and its value is 1.366, Φ is the fluorescence quantum yield of the donor and Φ = 0.118. J is the
overlap integral of the fluorescence emission spectrum of the donor and the absorption spectrum of
the acceptor [25]. J is given by Equation (7):
J = ∑
F(λ)ε(λ)λ4∆λ
∑ F(λ)∆λ
, (10)
where F(λ) is the fluorescence intensity of the fluorescent donor at wavelength, and ε(λ) is the
molar absorption coefficient of the acceptor at wavelength. The overlap of the absorption spectra of
compounds and the fluorescence emission spectra of BSA are shown in Figure 9 A–G. The calculated
R0 and r binding distances are showed in Table 4. A transfer of energy could take place through
direct electrodynamic interaction between the primarily excited molecule and its neighbors, when the
distance between the donor and the acceptor is approach in the range of 2–8 nm. As the distances
between BSA and compounds are 2–8 nm scale and 0.5R0 < r < 1.5R0, suggesting that the energy
transfer from BSA to compounds occurs with high probability. The calculated r-value was larger than
that of R0, further indicating that the fluorescence quenching of BSA induced by compounds 1–7 is the
result of a static quenching mechanism [27,28].
Table 4. Energy transfer parameters of the different compounds—BSA complexes.
Compounds J (cm3 L M−1) R0 (nm) r (nm) E (%)
1 7.70 × 10−15 2.35 2.72 29.30
2 9.90 × 10−15 2.45 2.62 39.97
3 1.05 × 10−14 2.47 2.62 41.25
4 1.44 × 10−14 2.60 2.79 39.69
5 1.16 × 10−14 2.51 2.69 39.98
6 6.47 × 10−15 2.28 2.42 41.23
7 8.50 × 10−15 2.39 2.64 35.20
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2.8. The determination of Binding Sites of Compound 6 on BSA
The BSA has been previously reported to have two major specific drug-binding sites, which are
defined as site I and site II, respectively. Binding site location for compound 6 was analyzed through
competitive binding assay and molecular docking, since this compound has the strongest activity.
Warfarin as the marker for site I and ibuprofen for site II as used in this experiment, respectively.
The concentration of the mark rs and BSA were both 5 µM, while the concentration of the compound
was 0–30 µM. Fluores enc emission spectra of the mixe solu ions of BSA and sit markers following
a concentration increment of compound 6 were recorded and the results were presented in Table 5.
It can be observed that the Kb and log Kb values of the compound with BSA decreased markedly in
the presence of warfarin and ibuprofen, indicating that there are competitive interactions between
compound 6 and the two site maker with BSA. Therefore, it can be deduced that the compound 6 may
interact with BSA at both site I and site II. Nevertheless, the value of Kb is much lower in the presence
of warfarin, suggesti g that site I is the main binding site.
Table 5. Binding constants of BSA with compound 6 in the presence of site markers in Tris-HCl buffer
(pH = 7.4) at room temperature.
System LogKb Kb (×105 L mol−1) R2
BSA + compound 6 4.662 0.459 0.993
BSA + compound 6 + ibuprofen 4.324 0.211 0.989
BSA + compound 6 + warfarin 3.227 0.017 0.993
Compound 6 was docked into the Site II (IIIA site) and Site I (IIA site) binding sites of the
BSA, respectively (Figure 10). The detailed binding mode of compound 6 to the Site II binding
site in subdomain IIIA of the BSA was shown in Figure 11. The acetyl group of compound 6 fit
at the bottom of the BSA pocket and made a high density of van der Waals contacts, whereas the
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rhamnopyranosyl group of compound 6 was positioned at the entrance of the pocket and makes
only a few contacts. Detailed analysis showed that the acetyl group of compound 6 stretched
into the hydrophobic pocket that consisted of Cys-391, Phe-402, Val-432 and Cys-437, while the
4-hydroxylphenyl group of compound 6 was located at another hydrophobic pocket, surrounded by
the residues Pro-383, Leu-386, Ile-387 and Leu-452, forming a stable hydrophobic binding. In addition,
cation-pi interactions were observed between the kaempferol scaffold of compound 6 and the residues
Arg-409, Lys-413 and Arg-484. Importantly, six hydrogen bond interactions were observed between
the compound 6 and the residues Thr-448, Arg-409 and Tyr-410 of the BSA.
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To gain further insight into the binding interaction between compound 6 and the BSA in the
molecular level, compound 6 was docked to the Site I of the BSA (Figure 12). The rhamnopyranosyl
group of compound 6 fit at the bottom of the BSA pocket and made a high density of van der
Waals contacts, whereas the other two sides of compound 6 were positioned near the entrance of the
pocket and makes only a few contacts. Detailed analysis showed that the acetyl group of compound
6 stretched into the hydrophobic pocket that consisted of Trp-213, Val-342 and Pro-446, while the
kaempferol scaffold of compound 6 was located at the hydrophobic pocket, surrounded by the residues
Ile-289, Ala-290 and Val-292, forming a stable hydrophobic binding. Moreover, cation-pi interactions
were observed between the kaempferol scaffold of compound 6 and the residues Arg-194, Arg-198,
Arg-217, Lys-221 and Lys-294. Importantly, six hydrogen bond interactions were observed between
the compound 6 and the residues Arg-194, Arg-198, Arg-217, and Lys-294. All of these interactions
helped compound 6 to anchor in the binding site of BSA. Molecular docking analysis suggests a better
binding interaction for compound 6 with site I, and this is consistent with the results of competitive
binding assay.
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In summary, the above molecular simulations give us a rational explanation of the interactions
between compound 6 and the BSA, which will provide a good structural basis to explain the
fluorescence quenching of BSA emission in the presence of compound 6.
The present study provided the detailed information about the binding characteristics and of
compounds 1–7 to BSA, which provides useful data for future pharmacological studies.
3. Materials and Methods
3.1. Chemicals and Instrumentation
Fatty acid-free BSA was obtained from Shanghai Shenhang Biotechnology Co., Ltd.
(Shanghai, China). The stock solution of compounds 1–7 was prepared in distilled water, respectively.
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All of the above solutions were kept in the dark at 0–4 ◦C. Tris–HCl buffer solution (0.05 mol L−1, pH
7.4) containing 0.1 mol L−1 NaCl were used. All reagents were of analytical reagent grade without
further purification and double distilled water was used throughout the experiment.
IR spectra were recorded on a Thermo-Nicolet 670 spectrophotometer (Madison, Wi. USA,) using
KBr disks. 1H and 13C-NMR spectra were recorded on a Bruker Advance 600 spectrometer (Fällanden,
Switzerland) at 600 (1H) and 150 (13C) MHz, respectively. High Resolution Electrospray ionization
Mass (HRESIMS) spectra were measured on an LTQ-Orbitrap XL (Thermo Electron., San Jose, CA,
USA). Fluorescence measurements were carried out on Cary Eclipse Fluorescence spectrophotometer
(Varian Australia Pty Ltd., Mulgrave, Australia), using a 1 cm quartz cell. The circular dichroism
(CD) spectra were recorded using Chirascan CD spectrophotometer (Applied Photophysics Ltd.,
Leatherhead, UK). Semi preparative HPLC was performed on an Agilent 1200 liquid chromatograph
(Germany) with a ZORBAX SB-C18 column (Agilent, CA, USA) (9.4 mm × 250 mm, 5 µm).
3.2. Plant Material
The roots of W. unigemmata were collected in Linyi, Shandong Province, P.R. China, in July 2015
and identified by Dr. Tao Shen, School of Pharmaceutical Sciences, Shandong University. A voucher
specimen (No. 201507GZ01) has been deposited at the Laboratory of Department of Natural Products
Chemistry, School of Pharmaceutical Sciences, Shandong University, China.
3.3. Extraction and Isolation
Powder of the dry rhizomes (2.0 kg) was extracted three times (72 h each) with EtOH-H2O (90:10)
at room temperature. After evaporation of the solvent in vacuo, the concentrate was suspended into
H2O and partitioned successively with petroleum ether (60–90 ◦C) (2000 mL× 3), EtOAc (2000 mL× 3)
and n-BuOH (2000 mL × 3). The n-BuOH layer was evaporated in vacuo to yield n-BuOH fraction
(15.0 g). The n-BuOH fraction was subjected to silica gel chromatographic column (CC) using a gradient
of CH2Cl2–MeOH (95:5–50:50) to give 7 sub-fractions (Fr.1–Fr.7). Sub-fraction Fr.2 was purified by
semi-HPLC using acetonitrile-H2O (40:60) at a flow rate of 2 mL/min to afford compound 1 (tR 9.5 min,
12 mg). Sub-fraction Fr.3 was separated by HPLC using acetonitrile-H2O (28:72) at a flow rate of
2 mL/min to obtain compound 2 (tR15.6 min, 13 mg), and 3 (tR 17.0 min, 8 mg). Sub-fraction Fr.4 was
conducted by HPLC using acetonitrile-H2O (22:78) at a flow rate of 2 mL/min to produce compound 4
(tR 12.4 min, 8 mg), 5 (tR 14.2 min, 8.5 mg), and 6 (tR 16.8 min, 10 mg). Sub-fraction Fr.5 was subjected
to HPLC using acetonitrile-H2O (22:78) at a flow rate of 2 mL/min to afford compound 7 (tR 5.7 min,
9 mg).
Compound 1: Yellow amorphous powder; UV (MeOH) λmax (logε) 265 (3.42), 340 (2.05) nm; IR
(KBr) νmax 3382, 2935, 1723, 1596, 1175 cm−1; 1H and 13C NMR see Table 1; HR-ESI-MS m/z 705.2027
[M + H]+ (calcd for C33H37O17, 705.2025).
3.4. Sugar Identification
L-Rhamnose (72 mg) and L-cysteine methyl ester hydrochloride (90 mg) were dissolved in pyridine
(3 mL) and stirred at 60 ◦C for 1.5 h, and then o-tolyl isothiocyanate (360 µL) was added to the mixture
and heated at 60 ◦C for 1.5 h. Separation by HPLC using a C-18 column eluted with H2O (containing
0.2% TFA)-CH3CN (65:35) gave the derivative S-1.
Compound 1 was hydrolyzed with 1% HCl and extracted with CH2Cl2. The aqueous layer was
passed through a Sephadex LH-20 column (Agilent, CA., USA) and the eluate was concentrated. The
residue was dissolved in pyridine (0.5 mL) and stirred with L-cysteine methyl ester (10 mg) for 1.5 h at
60 ◦C, and then o-tolyl isothiocyanate (40 µL) was added to the mixture and heated at 60 ◦C for 1.5 h.
The reaction mixture was analyzed by HPLC and detected by UV absorbance at 250 nm. Analytical
HPLC was performed on a Phenomenex C18 column (4.6 × 250 mm) (Torrance, CA, USA) at 30 ◦C
using a gradient of CH3CN: 0.15% TFA in H2O: 0–20 min (30:70), 20–30 min (30:70 to 70:30), 30–60
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min (70:30) as the mobile phase. Peaks were detected with an Agilent DAD detector. L-rhamnose was
identified as the sugar moieties of 1 as they had the same retention times with S-1 (tR 16.1 min) [12].
3.5. MTT Cytotoxicity Assay
The human leukemia cell line K562, and its multidrug-resistant counterpart K562/A02 were
obtained from the Department of Pharmacology, the Institute of Hematology of Chinese Academy of
Medical Sciences (Tianjin, China). K562/A02 cells were maintained in a complete RPMI-1640 medium
containing 1 µg/mL doxorubicin at 37 ◦C in a humidified atmosphere of 5% CO2. The cells were
cultured for two weeks in drug-free medium prior to their use in the experiments.
Cells were harvested and seeded into 96-well plates at 2 × 104 cells/well. For cytotoxicity
experiments, different concentrations (10, 20, 40, 80, and 160 µM) of compounds 1–7 were added into
designated wells, and for MDR reversal experiments, different concentrations (0.1, 0.2, 0.5, 1, 5, 10,
20, and 40 µM) of doxorubicin (DOX) were added into designated wells with or without compounds
1–7 (10 µM). After 48 h, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution
was added to each well, and the plate was further incubated for 4 h. The medium was discarded, and
200 µL of dimethyl sulphoxide (DMSO) was added into each well to dissolve the formazan crystal. The
absorbance in individual wells was determined at 570 nm with a Micro-Reader (BioTek instruments,
Inc., Winooski, VA., USA). IC50 values (concentration resulting in 50% inhibition of cell growth) for
compounds 1–7 and doxorubicin were calculated from plotted results using untreated cells as 100%.
The reversal fold (RF) values, as potency of reversal, were obtained from fitting the data to RF = IC50
of cytotoxic DOX alone/IC50 of cytotoxic DOX in the presence of the tested compounds [10].
3.6. BSA Binding Experiment
Fluorescence measurements were performed using a 1 cm quartz cell. The widths of excitation
and emission slit were set at 5.0 nm. The excitation wavelengths were set at 280 nm, and the emission
wavelength was recorded between 290 and 450 nm. The fluorescence intensities were corrected for
inner filter and dilution effects before analysis of the binding and quenching data. The concentration
of BSA during the experiment was 5 µM. Molar ratios of drug to protein used were 0, 1, 1.5, 2, 3, 4, 5
and 6.
Synchronous fluorescence spectra of all BSA solutions in the absence and presence of compounds
were obtained were recorded on Varian Cary Eclipse with 1 cm quartz cell at room temperature. The
scanning intervals of ∆λ (∆λ = λem − λex) were set at 15 and 60 nm, which were used to characterize
the properties of the tyrosine and tryptophan residues, respectively.
CD Spectra of free BSA (5 µM) and compounds (30 µM) were obtained by a Chirascan CD
spectrophotometer (Applied Photophysics Ltd., Leatherhead, UK) at room temperature. A quartz cell
with a path length of 1 mm was used to do measurements in the wavelength range of 200–400 nm.
Scan speed to obtain spectra was maintained at 164 nm/min with an interval of 1 nm.
Absorption measurements were carried out at room temperature on Shimadzu UV-2500 UV-VIS
Spectrophotometer (Suzhou, Jiangsu, China) using a 10 mm cell. Wavelength was recorded between
300 and 400 nm.
3.7. Molecule Modeling
Crystal structure of BSA (PDB ID: 4JK4) was obtained from Protein Data Bank [29]. The 2D
structure of the compound 6 was drawn by ChemBioDraw Ultra 12.0 (2010, CambridgeSoft, Cambridge,
MA., USA) and converted to 3D structure by ChemBio3D Ultra 12.0 software (CambridgeSoft,
Cambridge, MA., USA). The binding interactions of compound 6 with BSA were simulated by a
docking method implemented in AutoDock Vina (1.1.2, The Scripps Research Institute, La Jolla,
CA., USA) along with MGLTools (1.5.6, The Scripps Research InstituteManufacturer, La Jolla, CA.,
USA) [30–32]. A ligand was prepared for docking by merging non-polar hydrogen atoms and defining
rotatable bonds. The search grid of the BSA IIIA site (Site II) was identified as center_x: 100.77, center_y:
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28.293, and center_z: 36.82 with dimensions size_x: 15, size_y: 15, and size_z: 15, and the IIA site (Site I)
was identified as center_x: 95.873, center_y: 20.925, and center_z: 17.631 with dimensions size_x: 15,
size_y: 15, and size_z: 15. In order to increase the docking accuracy, the value of exhaustiveness was
set to 20. For Vina docking, the default parameters were used if it was not mentioned. The best-scoring
pose as judged by the Vina docking score was chosen and visually analyzed using PyMoL software
(1.3r1, DeLano Scientific LLC, South San Francisco, USA) [6].
4. Conclusions
In this work, seven compounds were isolated from the roots of Woodwardia unigemmata. The
structures of the compounds were elucidated by spectroscopic analysis, as well as by comparison with
literature data. Compound 6 showed comparable MDR reversing effect to verapamil. The interactions
between complexes 1–7 and BSA were investigated employing different spectroscopic and molecular
docking techniques. The experimental results indicated that these compounds bind to BSA by static
quenching mechanisms. The negative ∆H and ∆S values indicated that van der Waals interactions
and hydrogen bonds contributed in the binding of compounds 2–6 to BSA. On the other hand, for
compounds 1 and 7, the hydrophobic interactions play a major role on BSA binding. There are two
binding sites of compound 6 on BSA and the site I is the main one through the molecular docking and
competitive binding assay. Meanwhile, there is a slight change in the secondary structure of BSA after
the binding of compound 6.
The present study provided the detail information about the binding characteristics and
conformation of compounds 1–7 on BSA, which provide useful data for future pharmacological studies.
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